bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
After split, bluebird bio's new CEO looks to 'regain confidence' - Boston Business Journal
bluebird bio Completes Oncology Spin-Off Business, Establishes New Nest | BioSpace
Bluebird Bio Suspends Trials Evaluating LentiGlobin Gene Therapy for Sickle Cell
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
Where Will Bluebird Bio Be in 1 Year? | Nasdaq
bluebird bio plans 'new nest' around hybrid work model
Bristol Myers Squibb - Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application (BLA) For Anti-BCMA CAR T-Cell Therapy Idecabtagene Vicleucel (Ide-Cel, bb2121) To FDA
blue-ex991_6.htm
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
bluebird bio | LinkedIn
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
Bluebird bio Reports US FDA Acceptance of BLA for Priority Review of Lenti-D (elivaldogene autotemcel)
bluebird bio and Gritstone Oncology to Collaborate | INN
Erroneous announcement about bluebird's LentiGlobin prompts correction from company - MedCity News
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
BLUEBIRDBIO
2seventy bio discloses job cuts after split from bluebird - Boston Business Journal
